CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.
  
  LEARNING OBJECTIVES

  • Evaluate the importance of patient age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for various presentations of acute myeloid leukemia (AML).
  • Appreciate the FDA approval of venetoclax with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML who are 75 years or older or not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
  • Reflect on published research with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Understand the mechanisms of action of, available data with and current and emerging role of available IDH1/2 inhibitors for newly diagnosed or relapsed/refractory AML with an IDH1 or IDH2 mutation.
  • Assess the FDA-approved indication for CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
  • Formulate a treatment algorithm for lower- and higher-risk myelodysplastic syndromes (MDS), considering patient- and disease-related factors including cytogenetic abnormalities.
  • Develop an understanding of the biologic rationale for and available data with emerging novel combination regimens for higher-risk MDS to prepare for their potential availability in routine practice.
  • Recognize the recent FDA approval of the combination of decitabine and cedazuridine for intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
  • Recall promising agents and combination strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Richard M Stone, MD
  Lunder Family Chair in Leukemia
  Chief of Staff
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Arog Pharmaceuticals Inc, BerGenBio ASA, Boston Pharmaceuticals, Bristol-Myers Squibb Company, CTI BioPharma Corp, Epizyme Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Epizyme Inc, Takeda Pharmaceuticals USA Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Astellas, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, and Novartis.
  
  Release date: July 2022
  Expiration date: July 2023